Despite the benefits of anti-VEGF therapy, a number of observational studies have reported sustained ocular hypertension lasting several months or longer in 3% to 11% of patients receiving repeated injections of anti-VEGF.27, , , , , , , , –36 In our companion study37 we show that prolonged anti-VEGF therapy is associated with reduced tonographic outflow facility in patients receiving unilateral treatment for NVAMD. This evidence concerns the gene VEGFA and ocular hypertension.